For retail sale medicaments with insulin or hormones or antibiotics market in Bosnia and Herzegovina

Earlier Report Observations

Between 2018 and 2021, the market for packed retail medicaments containing insulin, hormones, or antibiotics in Bosnia and Herzegovina was shaped by a stringent regulatory framework and government policies aimed at industry growth. Tax reductions on pharmaceutical products and subsidies for generic drug production responded to high demand from chronic diseases like diabetes, while rising antibiotic consumption in 2019 further supported market demand.

After a decline to 54 960 K $ US in 2022, the market recovered to 59 413 K $ US in 2023, aided by the availability of generic alternatives that mitigated medicine supply interruptions reported by the Agency for Medicines and Medical Devices. In 2024, market size grew to 64 294 K $ US as the Agency planned new regulations to enhance healthcare quality and medicine provision, while efforts to streamline licensing aimed at preventing shortages.

By 2025, the Agency continued improving licensing processes to ensure market stability, and the Council of Ministers approved the legalization of medical cannabis effective from January 2026, introducing a new pharmaceutical segment. Industry growth remains underpinned by government policies, low labor costs, and ongoing alignment with EU regulations, with domestic companies like Bosnalijek maintaining leadership through investment in knowledge and technology.

Production for retail sale medicaments with insulin or hormones or antibiotics in Bosnia and Herzegovina

In value, 2018-2021, K $ US

Annual dynamics of production in Bosnia and Herzegovina in value, 2018-2021, K $ US

Exports for retail sale medicaments with insulin or hormones or antibiotics from Bosnia and Herzegovina

Exports in kind, t

In 2021, Bosnia and Herzegovina exported 3.7 tonnes of retail sale medicaments containing insulin, hormones, or antibiotics, marking a 22.3% increase compared to the previous year. Exports reached their lowest point in 2020 at 3.1 tonnes, with the largest decline of 9.6% recorded that same year. Over the period from 2018 to 2021, exports grew by 12.5%, translating to an average annual growth rate of 4.0%.

Annual dynamics of product's exports from Bosnia and Herzegovina in kind, 2018-2021, t

From 2018 to 2021, Serbia was the leading buyer of retail sale medicaments with insulin, hormones, or antibiotics from Bosnia and Herzegovina, accounting for 48.9% of exports in kind. Moldova followed with 22.8%, and Libya with 11.2%. Together, these three countries represented 82.9% of total exports in kind during this period.

Structure of product's exports in kind by countries, 2018-2021

World map of product's exports from Bosnia and Herzegovina in kind, 2018-2021

Exports in value, K $ US

In 2021, the value of Bosnia and Herzegovina's exports of retail sale medicaments containing insulin, hormones, or antibiotics reached 387 thousand US dollars, a 40.6% rise from the previous year. The largest decline occurred in 2020, with a drop of 2.7%. Between 2018 and 2021, exports increased by 48.1%, corresponding to a compound annual growth rate of 14.0%.

Annual dynamics of product's exports from Bosnia and Herzegovina in value, 2018-2021, K $ US

During 2018–2021, Serbia dominated the value of exports for retail sale medicaments with insulin, hormones, or antibiotics from Bosnia and Herzegovina, making up 60.4% of the total. Moldova contributed 17.2%, and Albania 7.1%. Collectively, these three partners accounted for 84.7% of the total export value.

Structure of product's exports in value by countries, 2018-2021

World map of product's exports from Bosnia and Herzegovina in value, 2018-2021

Imports for retail sale medicaments with insulin or hormones or antibiotics to Bosnia and Herzegovina

Imports in kind, t

Bosnia and Herzegovina's imports of retail sale medicaments with insulin, hormones, or antibiotics grew for the third consecutive year. In 2021, imports totaled 220.1 tonnes, showing a moderate increase of 8.2% compared to the previous year. From 2018 to 2021, imports rose by 36.4%, which equates to an average annual growth rate of 10.9%.

Annual dynamics of product's imports to Bosnia and Herzegovina in kind, 2018-2021, t

Between 2018 and 2021, France was the largest source of imports in kind for retail sale medicaments containing insulin, hormones, or antibiotics, representing 23.6% of the total. Germany accounted for 19.1%, and Italy for 18.1%. Together, these three countries comprised 60.8% of total imports in kind.

Structure of product's imports in kind by countries, 2018-2021

World map of product's imports to Bosnia and Herzegovina in kind, 2018-2021

Imports in value, K $ US

Bosnia and Herzegovina's imports of retail sale medicaments with insulin, hormones, or antibiotics continued to rise for the third year in a row. In 2021, imports amounted to 57 553 thousand US dollars, up by 10.0% from 2020. Over the period from 2018 to 2021, imports increased by 20.7%, with a compound annual growth rate of 6.5%.

Annual dynamics of product's imports to Bosnia and Herzegovina in value, 2018-2021, K $ US

From 2018 to 2021, Germany was the primary market for imports in value terms of retail sale medicaments containing insulin, hormones, or antibiotics to Bosnia and Herzegovina, holding a 25.1% share. France followed with 21.7%, and Denmark with 17.2%. These three countries together accounted for 64.0% of total import value.

Structure of product's imports in value by countries, 2018-2021

World map of product's imports to Bosnia and Herzegovina in value, 2018-2021